Geneuro Innovation SAS

Geneuro Innovation SAS est membre de Lyonbiopôle

General information

60 avenue de Rockefeller

69008 Lyon

Incorporated in: 2009/02/18

Number of employees: 15

Turnover: €1M (in 2017)

More information


Main activity

Geneuro is a product development company, developing a pioneering approach for the therapy of diseases associated with human endogeneous retrovirus expression, with a primary focus on nervous system diseases. Geneuro anticipates the first clinical trial of its monoclonal antibody early 2011 in multiple sclerosis and also carries out extensive preclinical research in other diseases such as schizophrenia. Geneuro breakthrough innovation targets the envelope protein of human endegeneous retrovirus. Its lead product, a monoclonal antibody, acts upstream of the pro-inflammatory cascade, thus increasing efficacy and safety over existing drugs which mainly delay neurological damages and disability caused by Multiple sclerosis. Geneuro is driven by entrepreneurial spirit and supported by a well established network of worldwide leading industrial and academic partners.


Public funding obtained: No

Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine

Application market
Immune, AutoIm & Inflam. diseases - Neurological diseases

Therapeutics, Pharma or Biotech

Antibodies - Protein - Peptide